Xiaojuan Wang1, Changdong Hu1, Yisong Chen2, Keqin Hua3. 1. Department of Gynecology, The Obstetrics and Gynecology Hospital of Fudan University, 128 Shenyang Road, Shanghai, China. 2. Department of Gynecology, The Obstetrics and Gynecology Hospital of Fudan University, 128 Shenyang Road, Shanghai, China. cys373900207@aliyun.com. 3. Department of Gynecology, The Obstetrics and Gynecology Hospital of Fudan University, 128 Shenyang Road, Shanghai, China. huakeqinjiaoshou@163.com.
Abstract
INTRODUCTION AND HYPOTHESIS: The causes of recurrence of pelvic organ prolapse (POP) are sufficiently understood. However, few studies are available evaluating reoperation for recurrence of POP. This study evaluates the efficacy and safety of LeFort colpocleisis for recurrent POP. METHODS: We reviewed data from patients with recurrent POP who underwent LerFort colpocleisis at a center between March 2012 and April 2017. Quality of life was assessed using the Pelvic Floor Distress Inventory Questionnaire (PFDI-20) scores. The Patient Global Impression of Improvement scale (PGI-I) was used to assess self-perceived success and subjective measures of satisfaction. The Clavien-Dindo classification (CD) was used to assess the safety of the procedure. Chi-square and paired t-tests were used to compare the same patients before and after treatment in the follow-up. RESULTS: Twenty-six patients with recurrent POP after previous prolapse surgery underwent LeFort colpocleisis. Most of these patients had at least one comorbidity. The mean age (years) was 71.8 (7.3). The mean time to recurrent POP was 5.602 (3.643) years. There were no intraoperative bladder lesions or rectal lesions. At mean follow-up of 33.1 months, all patients had no recurrence (< stage 2), significant resolution of awareness of prolapse (P < 0.05), and significantly improved satisfaction on PGI-I after surgery. Minor complications were classified as CD II level in four cases (15.4%). CONCLUSION: This study suggests that LeFort colpocleisis is feasible and safe for recurrent POP, especially in older women with comorbidities.
INTRODUCTION AND HYPOTHESIS: The causes of recurrence of pelvic organ prolapse (POP) are sufficiently understood. However, few studies are available evaluating reoperation for recurrence of POP. This study evaluates the efficacy and safety of LeFort colpocleisis for recurrent POP. METHODS: We reviewed data from patients with recurrent POP who underwent LerFort colpocleisis at a center between March 2012 and April 2017. Quality of life was assessed using the Pelvic Floor Distress Inventory Questionnaire (PFDI-20) scores. The Patient Global Impression of Improvement scale (PGI-I) was used to assess self-perceived success and subjective measures of satisfaction. The Clavien-Dindo classification (CD) was used to assess the safety of the procedure. Chi-square and paired t-tests were used to compare the same patients before and after treatment in the follow-up. RESULTS: Twenty-six patients with recurrent POP after previous prolapse surgery underwent LeFort colpocleisis. Most of these patients had at least one comorbidity. The mean age (years) was 71.8 (7.3). The mean time to recurrent POP was 5.602 (3.643) years. There were no intraoperative bladder lesions or rectal lesions. At mean follow-up of 33.1 months, all patients had no recurrence (< stage 2), significant resolution of awareness of prolapse (P < 0.05), and significantly improved satisfaction on PGI-I after surgery. Minor complications were classified as CD II level in four cases (15.4%). CONCLUSION: This study suggests that LeFort colpocleisis is feasible and safe for recurrent POP, especially in older women with comorbidities.
Entities:
Keywords:
LeFort colpocleisis; Pelvic organ prolapse; Recurrence
Authors: Bernard T Haylen; Robert M Freeman; Joseph Lee; Steven E Swift; Michel Cosson; Jan Deprest; Peter L Dwyer; Brigitte Fatton; Ervin Kocjancic; Chris Maher; Eckhard Petri; Diaa E Rizk; Gabriel N Schaer; Ralph Webb Journal: Neurourol Urodyn Date: 2012-04 Impact factor: 2.696
Authors: Erin Seifert Lavelle; Lauren E Giugale; Daniel G Winger; Li Wang; Charelle M Carter-Brooks; Jonathan P Shepherd Journal: Am J Obstet Gynecol Date: 2017-09-23 Impact factor: 8.661
Authors: Michele Jonsson Funk; Anthony G Visco; Alison C Weidner; Virginia Pate; Jennifer M Wu Journal: Int Urogynecol J Date: 2013-02-12 Impact factor: 2.894